BCR-ABL 1 Kinase Domain Mutation Analysis (IRMA), EDTA Blood near me in Meerut

The BCR-ABL 1 Kinase Domain Mutation Analysis (IRMA), EDTA Blood, also known as Imatinib Resistance Mutation Analysis (IRMA) test is performed in patients suffering from Chronic Myelogenous Leukemia (CML), to determine the dosage of the Imatinib that the patient needs. CML cells have BCR-ABL, an abnormal gene, which is an oncoprotein that is targeted by the Tyrosine Kinase Inhibitor called Imatinib, as the main treatment procedure.

Please note: This is an outsourced test. The sample for this test is collected by TATA 1MG and processed at a NABL accredited partnered lab.